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Background: There is limited information about the outcome of patients with Transthretin (ATTR) cardiac amyloidosis (CA) after disease diagnosis. 
Methods: A total of 24 patients endomyocardial biopsy proven CA was retrospectively analyzed. 
Results: All CA was classified into 17 ATTR amyloidosis and 7 AL amyloidosis by immunohistochemical typing of amyloid protein. Patients with 
ATTR amyloidosis were older than AL amyloidoisis (77.7±6.8 years vs 68.5±5.4 years, p<0.05). Compared with AL amyloidoisis, male accounts for 
nearly all of the ATTR amyloidosis (94.1% (16/17) vs 57.1% (4/7), p<0.05). On the echocardiogram, left ventricular wall thickness was greater in 
patients with ATTR amyloidosis than AL amyloidosis (interventricular septum 15.2±2.2mm vs 12.5±2.1mm, p<0.05, left ventricular posterior wall 
15.0±2.9mm vs 12.1±2.3mm, p<0.05). B-natriuretic peptide were lower in patients with ATTR amyloidosis than AL amyloidosis (620±638pg/ml vs 
1417±970pg/ml, p<0.05). During 2-year follow up, ATTR amyloidosis showed a better prognosis for mortality than AL amyloidosis (13.3% vs 100%, 
p=0.002), however combined event rate of hospitalization for heart failure or MACCE (major adverse cardiac and cerebrovascular events) were 
comparable between both groups (70.0% vs 85.7%, p=0.023). 
Conclusions: In CA, although prognosis of ATTR amyloisosis was better than AL amyloidosis, ATTR amyloidosis is not indolent, considering its high 
event rate.
 
